Journal of Clinical Oncology, Vol 25, No 2 (January 10), 2007: pp. 180-186
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.09.6081
Cost of Cancer Care: Issues and Implications
Neal J. Meropol,
Kevin A. Schulman
From the Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA; and the Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Address reprint requests to Neal J. Meropol, MD, Fox Chase Cancer Center, 333 Cottman Ave, Room C307, Philadelphia, PA 19111; e-mail: neal.meropol{at}fccc.edu
Medical technology is increasingly costly in most fields of clinical medicine. Oncology has not been spared from issues related to cost, in part resulting from the tremendous scientific progress that has lead to new tools for diagnosis, treatment, and follow-up of our patients. The increasing cost of health care in general (and cancer care in particular) raises complex questions related to its effects on our economy and the citizens of our society. This article reviews the macroeconomic principles and individual behaviors that govern medical spending, and examines how cost disproportionately affects various populations. Our overall goal is to frame debate about health policy concerns that influence the clinical practice of oncology.
Presented in part in written format in the 2005 Ameican Society of Clinical Oncology Educational Book.
Authors' discolsures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. J. Smith and B. E. Hillner
Concrete Options and Ideas for Increasing Value in Oncology Care: The View from One Trench
Oncologist,
March 1, 2010;
15(suppl_1):
65 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schickedanz
Of Value: A Discussion of Cost, Communication, and Evidence to Improve Cancer Care
Oncologist,
March 1, 2010;
15(suppl_1):
73 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Greenberg, C. Earle, C.-H. Fang, A. Eldar-Lissai, and P. J. Neumann
When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology
J Natl Cancer Inst,
January 20, 2010;
102(2):
82 - 88.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Saif, A. Choma, S. J. Salamone, and E. Chu
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
J Natl Cancer Inst,
November 18, 2009;
101(22):
1543 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Luna, P. W. Thurman, M. Wolfe, D. Yagoda, E. Reed, and W. D. Figg Sr
Private Practice Administrative Costs Influenced by Insurance Payer Mix
J. Oncol. Pract,
November 1, 2009;
5(6):
291 - 297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Yabroff and D. Schrag
Challenges and Opportunities for Use of Cost-Effectiveness Analysis
J Natl Cancer Inst,
September 2, 2009;
101(17):
1161 - 1163.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol, D. Schrag, T. J. Smith, T. M. Mulvey, R. M. Langdon Jr, D. Blum, P. A. Ubel, and L. E. Schnipper
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
J. Clin. Oncol.,
August 10, 2009;
27(23):
3868 - 3874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Anderson
Cancer Surveillance Research
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2009;
18(6):
1669 - 1671.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Reed, Y. Li, K. J. Anstrom, and K. A. Schulman
Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol.,
May 1, 2009;
27(13):
2185 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Wilson
Cancer Care: A Microcosm of the Problems Facing All of Health Care
Ann Intern Med,
April 21, 2009;
150(8):
573 - 576.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Bach
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
N. Engl. J. Med.,
February 5, 2009;
360(6):
626 - 633.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Peppercorn, H. Burstein, F. G. Miller, E. Winer, and S. Joffe
Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy
J. Clin. Oncol.,
December 20, 2008;
26(36):
5994 - 6000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. McFarlane, J. Riggins, and T. J. Smith
SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care
J. Clin. Oncol.,
September 1, 2008;
26(25):
4200 - 4204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-C. T. Shih and M. T. Halpern
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin,
July 1, 2008;
58(4):
231 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Hozo and B. Djulbegovic
When Is Diagnostic Testing Inappropriate or Irrational? Acceptable Regret Approach
Med Decis Making,
July 1, 2008;
28(4):
540 - 553.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. E. Harrington and T. J. Smith
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"
JAMA,
June 11, 2008;
299(22):
2667 - 2678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Mayer
Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?
J. Clin. Oncol.,
September 20, 2007;
25(27):
4165 - 4167.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol and K. A. Schulman
In Reply
J. Clin. Oncol.,
August 1, 2007;
25(22):
3383 - 3383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Meropol and K. A. Schulman
Perspectives on the Cost of Cancer Care
J. Clin. Oncol.,
January 10, 2007;
25(2):
169 - 170.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Grusenmeyer and Y.-N. Wong
Interpreting the Economic Literature in Oncology
J. Clin. Oncol.,
January 10, 2007;
25(2):
196 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
